Human CD19 Antibody

Name: Human CD19 Antibody
Brand: R&D Systems
SKU: MAB11717
Price: 449 USD
Availability: InStock

R&D Systems | Catalog # MAB11717

Submit a review

Product Documents

View Available Conjugates

100% Guarantee

Product Specifications
Scientific Data
Applications
Preparation & Storage
Calculators
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

Species Reactivity

Human

Applications

Multiplex Immunofluorescence, Immunohistochemistry, Western Blot, Immunocytochemistry, COMET

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG_2B Clone # 1062909

View all CD19 Primary Antibodies »

Product Specifications

Immunogen

Chinese Hamster Ovary cell line, CHO-derived human CD19
Met1-Lys291
Accession # P15391

Specificity

Detects recombinant human CD19 protein in Direct ELISA.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG_2B

Scientific Data Images for Human CD19 Antibody

Detection of CD19 in Human spleen via seqIF™ staining on COMET™

CD19 was detected in immersion fixed paraffin-embedded sections of human spleen using Mouse Anti-Human CD19, Monoclonal Antibody (Catalog #MAB11717) at 5ug/mL at 37 ° Celsius for 4 minutes. Before incubation with the primary antibody, tissue underwent an all-in-one dewaxing and antigen retrieval preprocessing using PreTreatment Module (PT Module) and Dewax and HIER Buffer H (pH 9; Epredia Catalog # TA-999-DHBH).Tissue was stained using the Alexa Fluor™ 647 Goat anti-Mouse IgG Secondary Antibody at 1:200 at 37 ° Celsius for 2 minutes. (Yellow; Lunaphore Catalog # DR647MS) and counterstained with DAPI (blue; Lunaphore Catalog # DR100). Specific staining was localized to the membrane. Protocol available in COMET™ Panel Builder.

Detection of Human CD19 by Western Blot.

Western Blot shows lysates of Raji human Burkitt's lymphoma cell line and NC‑37 human Burkitt's lymphoma B lymphoblast cell line. PVDF membrane was probed with 2 µg/ml of Mouse Anti-Human CD19 Monoclonal Antibody (Catalog # MAB11717) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for CD19 at approximately 95 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.

Detection of CD19 in Human B-cell Lymphoma.

CD19 was detected in immersion fixed paraffin-embedded sections of human b-cell lymphoma using Mouse Anti-Human CD19 Monoclonal Antibody (Catalog # MAB11717) at 5 µg/ml for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001) or the HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the membrane. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Detection of CD19 in Human Spleen.

CD19 was detected in immersion fixed paraffin-embedded sections of human spleen using Mouse Anti-Human CD19 Monoclonal Antibody (Catalog # MAB11717) at 5 µg/ml for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001) or the HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the membrane in the white pulp of spleen. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Detection of CD19 in Human Tonsil.

CD19 was detected in immersion fixed paraffin-embedded sections of human tonsil using Mouse Anti-Human CD19 Monoclonal Antibody (Catalog # MAB11717) at 5 µg/ml for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001) or the HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the membrane. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Detection of CD19 in Daudi cells.

CD19 was detected in immersion fixed Daudi human Burkitt's lymphoma cell line (Positive) and absent in U266 human myeloma cell line (Negative) using Mouse Anti-Human CD19 Monoclonal Antibody (Catalog # MAB11717) at 8 µg/ml for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to the membrane of Daudi cells. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

View 3 more images

Applications for Human CD19 Antibody

Application

Recommended Usage

COMET

Optimal dilutions of this antibody should be experimentally determined.

Immunocytochemistry

3-25 µg/mL
Sample: Immersion fixed Daudi human Burkitt's lymphoma cell line

Immunohistochemistry

3-25 µg/mL
Sample: Immersion fixed paraffin-embedded sections of human B-cell lymphoma, spleen, and tonsil

Multiplex Immunofluorescence

5 µg/mL
Sample: Immersion fixed paraffin-embedded sections of human spleen

Western Blot

2 µg/mL
Sample: Raji human Burkitt's lymphoma cell line and NC-37 human Burkitt's lymphoma B lymphoblast cell line

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute lyophilized material at 0.2 mg/ml in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: CD19

CD19, also known as B4, is a transmembrane glycoprotein of the immunoglobulin superfamily that plays a central role in B cell activation and humoral immune responses (1, 2). CD19 consists of an extracellular domain (ECD) with two C2-type Ig-like domains, a transmembrane segment, and a cytoplasmic domain with nine tyrosine residues, 3 of which are critical for function (1, 2). Within the mature ECD, human CD19 shares 57% amino acid sequence identity with mouse and rat CD19. CD19 is expressed throughout B cell development from pre‑B cells through mature B cells, and it is commonly used as a B cell lineage marker (1, 2). It is required for the responsiveness of mature B cell to antigen stimulation, germinal center development, and antibody affinity maturation (1, 2). CD19 associates with the B cell antigen receptor (BCR), CD81, CD38, CD21, CD22, and IFITM1/CD225/Leu-13 (1, 3). These associations enable CD19 to amplify B cell signaling and reduce the threshold for antigen stimulation through the BCR (1, 3). CD19 polymorphisms and up-regulation can lead to the development of autoimmunity by promoting autoantibody production (2). CD19 has emerged as promising therapeutic target for hematologic cancers and solid tumors, such as leukemias and lymphomas (4, 5). Immunotherapy using a chimeric antigen receptor (CAR) targeting CD19 has emerged as promising therapeutic target for hematologic cancers and solid tumors, such as leukemias and lymphomas (4, 5). The first CD19 CAR T cell therapies have been granted FDA approval for the treatment of B cell malignancies with several more in clinical trials (6).